These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18640168)

  • 21. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen.
    Sim AC; Lin W; Tan GK; Sim MS; Chow VT; Alonso S
    Vaccine; 2008 Feb; 26(9):1145-54. PubMed ID: 18243432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses.
    Chiang CY; Huang MH; Hsieh CH; Chen MY; Liu HH; Tsai JP; Li YS; Chang CY; Liu SJ; Chong P; Leng CH; Chen HW
    PLoS Negl Trop Dis; 2012; 6(5):e1645. PubMed ID: 22616020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity.
    Chiang CY; Hsieh CH; Chen MY; Tsai JP; Liu HH; Liu SJ; Chong P; Leng CH; Chen HW
    Vaccine; 2014 Mar; 32(12):1346-53. PubMed ID: 24486311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates.
    Chen HW; Liu SJ; Li YS; Liu HH; Tsai JP; Chiang CY; Chen MY; Hwang CS; Huang CC; Hu HM; Chung HH; Wu SH; Chong P; Leng CH; Pan CH
    Arch Virol; 2013 Jul; 158(7):1523-31. PubMed ID: 23456422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.
    Pattnaik P; Shakri AR; Singh S; Goel S; Mukherjee P; Chitnis CE
    Vaccine; 2007 Jan; 25(5):806-13. PubMed ID: 17045706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of antibody- and cell-mediated immune responses after intramuscular hepatitis C immunizations of BALB/c mice.
    Ghorbani M; Nass T; Azizi A; Soare C; Aucoin S; Giulivi A; Anderson DE; Diaz-Mitoma F
    Viral Immunol; 2005; 18(4):637-48. PubMed ID: 16359230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.
    Hermida L; Bernardo L; Martín J; Alvarez M; Prado I; López C; Sierra Bde L; Martínez R; Rodríguez R; Zulueta A; Pérez AB; Lazo L; Rosario D; Guillén G; Guzmán MG
    Vaccine; 2006 Apr; 24(16):3165-71. PubMed ID: 16490289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs.
    Sugauchi F; Wang RY; Qiu Q; Jin B; Alter HJ; Shih JW
    J Infect Dis; 2006 Feb; 193(4):563-72. PubMed ID: 16425136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effects of inoculation route and adjuvant type on the immunizing potency of CVB3 VP1 protein].
    Wen C; Gao ZY; Lan JM; Yan LJ; Chuai X; Li J; Li W; Wang YX
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Oct; 27(10):1086-9. PubMed ID: 21968309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II.
    Rocha RP; Livonesi MC; Fumagalli MJ; Rodrigues NF; da Costa LC; Dos Santos MC; de Oliveira Rocha ES; Kroon EG; Malaquias LC; Coelho LF
    Virus Res; 2014 Aug; 188():122-7. PubMed ID: 24768848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of robust immunity by the emulsification of recombinant lipidated dengue-1 envelope protein domain III.
    Chiang CY; Huang MH; Pan CH; Hsieh CH; Chen MY; Liu HH; Tsai JP; Liu SJ; Chong P; Leng CH; Chen HW
    Microbes Infect; 2013; 15(10-11):719-28. PubMed ID: 23774693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines.
    Osorio Y; Cohen J; Ghiasi H
    Invest Ophthalmol Vis Sci; 2004 Feb; 45(2):506-14. PubMed ID: 14744892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development.
    Huijbers EJ; Femel J; Andersson K; Björkelund H; Hellman L; Olsson AK
    Vaccine; 2012 Jan; 30(2):225-30. PubMed ID: 22079080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gp96 enhances the immunogenicity of subunit vaccine of porcine reproductive and respiratory syndrome virus.
    Chen C; Li J; Bi Y; Jia X; Meng S; Sun L; Liu W
    Virus Res; 2012 Aug; 167(2):162-72. PubMed ID: 22561908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice.
    Bernardo L; Pavón A; Hermida L; Gil L; Valdés I; Cabezas S; Linares R; Alvarez M; Silva R; Guillén G; Nagy E; Schlick P; Guzmán MG
    Vaccine; 2011 Jun; 29(25):4256-63. PubMed ID: 21447316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization with Leishmania vaccine-alum-BCG and montanide ISA 720 adjuvants induces low-grade type 2 cytokines and high levels of IgG2 subclass antibodies in the vervet monkey (Chlorocebus aethiops) model.
    Mutiso JM; Macharia JC; Gicheru MM
    Scand J Immunol; 2012 Nov; 76(5):471-7. PubMed ID: 22862788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis.
    Valdés I; Hermida L; Martín J; Menéndez T; Gil L; Lazo L; Castro J; Niebla O; López C; Bernardo L; Sánchez J; Romero Y; Martínez R; Guzmán MG; Guillén G
    Vaccine; 2009 Feb; 27(7):995-1001. PubMed ID: 19100804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.